Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer

(Image credit: AdobeStock/Macrostock)

Tenpoint Therapeutics Ltd. appoints Carol Kearney as Chief Commercial Officer (CCO). Kearney will lead Tenpoint’s commercial strategy, including preparation of the potential US launch of BRIMOCHOL PF, an investigational, preservative-free, once-daily eye drop designed to address the loss of near vision.

Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, shared his thoughts on Kearney’s new role, saying, “The appointment of Carol as our first Chief Commercial Officer is an important step forward in Tenpoint’s growth. With her extensive experience in ophthalmology and her commercial leadership, I am confident in Carol’s ability to quickly scale up our commercial efforts and prepare for a successful launch of BRIMOCHOL PF. We look forward to building a world-class commercial team under her leadership.”

According to the news release, Tenpoint has shared that Kearney is an established commercialization executive with more than 2 decades of leadership experience in the biopharmaceutical industry, working with both private and publicly traded biotech companies. As Tenpoint’s first CCO, she will lead the company’s global expansion from a clinical-stage entity to a market-leading commercial organization.

Kearney’s biography was also included in the company’s release. It states that, most recently, Kearney served as Senior Vice President, Strategy Consulting at Lumanity, Inc., formerly Clarion Healthcare, Inc., where she engaged with biopharmaceutical companies, business units and brands to define strategies to accelerate growth, overcome challenges and deliver results. During her tenure, Kearney led numerous engagements supporting clients to scale up their organizations and successfully launch new products into the marketplace. Additionally, Kearney has a robust understanding of ophthalmology and optometry having previously worked in Global Marketing for Pfizer and Pharmacia, and in sales and marketing for Bausch & Lomb as well as for a broad range of ophthalmic companies developing products for conditions affecting both the anterior and posterior segments of the eye.

Reference:

1. Tenpoint Therapeutics Ltd. Appoints Carol Kearney as Chief Commercial Officer. Tenpoint Therapeutics Ltd. March 11, 2025. Accessed March 11, 2025. https://www.businesswire.com/news/home/20250311115875/en/Tenpoint-Therapeutics-Ltd.-Appoints-Carol-Kearney-as-Chief-Commercial-Officer